The Predictive Role of HPV Integration in HSIL and Cervical Cancer

Tongji Hospital1 enrolled

Overview

The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HPV Integration

Interventions

HPV integration testDIAGNOSTIC_TEST

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * HPV-positive patients； Patients have completed HPV detection, TCT, and HPV integration detection before surgery or biopsy； Patients with priced diagnoses accepted treatment according to ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors； Patients who are voluntary participants in this research and cooperate to follow-up with subscribing informed consent. Exclusion Criteria: * Patients who are not suitable for the trial； Patients existing other subtype malignancy tumors are still in treatment.

Locations (1)

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

Tissue pathological diagnosis

Tissue pathological diagnosis in 1 year since HPV integrated test

Time frame: 1year since HPV integrated test

Central Contacts

Shuang Li, PHD

CONTACT

+86 18971625668 shuangli@hust.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.